Royal Bank of Canada
PHAT icon

Royal Bank of Canada’s Phathom Pharmaceuticals PHAT Stock Holding History

Royal Bank of Canada’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64K Sell
5,766
-16,788
-74% -$212K ﹤0.01% 5363
2025
Q4 		$374K Sell
22,554
-139,889
-86% -$2M ﹤0.01% 4371
2025
Q3 		$1.91M Buy
162,443
+4,502
+3% +$46.5K ﹤0.01% 3447
2025
Q2 		$1.51M Buy
157,941
+147,759
+1,451% +$818K ﹤0.01% 3541
2025
Q1 		$64K Sell
10,182
-1,405
-12% -$8.53K ﹤0.01% 5458
2024
Q4 		$94K Buy
11,587
+4,581
+65% +$56.7K ﹤0.01% 5372
2024
Q3 		$126K Buy
7,006
+2,753
+65% +$38.5K ﹤0.01% 5179
2024
Q2 		$44K Buy
4,253
+2,237
+111% +$23K ﹤0.01% 5718
2024
Q1 		$22K Sell
2,016
-8,416
-81% -$71.5K ﹤0.01% 5880
2023
Q4 		$94K Buy
10,432
+4,716
+83% +$40.6K ﹤0.01% 5658
2023
Q3 		$59K Buy
5,716
+3,214
+128% +$44.1K ﹤0.01% 5697
2023
Q2 		$36K Buy
2,502
+617
+33% +$7.11K ﹤0.01% 5934
2023
Q1 		$13K Sell
1,885
-2,254
-54% -$19.8K ﹤0.01% 6203
2022
Q4 		$46K Buy
4,139
+3,859
+1,378% +$39.8K ﹤0.01% 5938
2022
Q3 		$3K Buy
280
+150
+115% +$1.43K ﹤0.01% 6913
2022
Q2 		$1K Sell
130
-1,114
-90% -$11.5K ﹤0.01% 7175
2022
Q1 		$17K Sell
1,244
-3,203
-72% -$51.7K ﹤0.01% 6693
2021
Q4 		$87K Buy
4,447
+2,579
+138% +$60.7K ﹤0.01% 6034
2021
Q3 		$60K Buy
1,868
+481
+35% +$16K ﹤0.01% 6053
2021
Q2 		$47K Buy
1,387
+725
+110% +$26K ﹤0.01% 6083
2021
Q1 		$25K Buy
+662
New +$27.7K ﹤0.01% 6304
2020
Q4 		– Sell
-7
Closed – – 7232
2020
Q3 		$0 Sell
7
-13
-65% -$450 ﹤0.01% 6853
2020
Q2 		$1K Sell
20
-494
-96% -$19K ﹤0.01% 6467
2020
Q1 		$13K Sell
514
-179
-26% -$5.98K ﹤0.01% 5735
2019
Q4 		$22K Buy
+693
New +$17.4K ﹤0.01% 5818

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Royal Bank of Canada's PHAT Position: Q1 2026 in Review

Royal Bank of Canada reduced its Phathom Pharmaceuticals (PHAT) stake by 74% in Q1 2026, selling an estimated $212K and leaving 5,766 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #5363.

Royal Bank of Canada first reported a position in PHAT in Q4 2019 and has held it in 25 quarters since. The position peaked at $1.91M in Q3 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Royal Bank of Canada held 5,766 shares of Phathom Pharmaceuticals worth $64K as of Q1 2026.
  • Royal Bank of Canada sold 16,788 Phathom Pharmaceuticals shares in Q1 2026, an estimated $212K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5363 holding.
  • Royal Bank of Canada first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
  • Royal Bank of Canada's Phathom Pharmaceuticals position peaked at $1.91M in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.